Application
Immunohistochemical analysis of paraffin-embedded human pancreas tissue using Raf1 (Phospho-Tyr341) antibody (left) or the same antibody preincubated with blocking peptide (right).Application
Western blot analysis of extracts from Jurkat cells treated with Paclitaxel using Raf1 (Phospho-Tyr341) Antibody. The lane on the right is treated with the antigen-specific peptide.| Product Name | C-RAF (phospho Tyr341) Antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | C-RAF, C-Raf, CRAF, RAF-1 |
| Product description | Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.1) David R. Hodge, J. Biol. Chem., Jun 1998; 273: 15727. |
| Immunogen | C-RAF (phospho Tyr341) antibody was raised against a peptide sequence around phosphorylation site of tyrosine 341 (S-Y-Y (p)-W-E) derived from Human C-RAF . |
| Modification | p-Tyr341 |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | IHCWB |
| Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100: |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Gene Symbol | RAF1 |
|---|---|
| Alternative Names | C-RAF C-Raf CRAF RAF-1 |
| Molecular Weight(MW) | 74 kDa |
| Tissue Specificity | The antibody detects endogenous levels of Raf1 only when phosphorylated at tyrosine 341. |
| Entrez Gene | 5894 |
|---|---|
| Protein Accession | NP_002871.1 |
Application
Immunohistochemical analysis of paraffin-embedded human pancreas tissue using Raf1 (Phospho-Tyr341) antibody (left) or the same antibody preincubated with blocking peptide (right).
Application
Western blot analysis of extracts from Jurkat cells treated with Paclitaxel using Raf1 (Phospho-Tyr341) Antibody. The lane on the right is treated with the antigen-specific peptide.| Application Notes | Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Store antibody at -20˚C for up to one year. |
| Storage Buffer | Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
